GlobeImmune, Inc.

Equities

GBIM

US37957B1008

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:43:20 2024-03-14 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

2022	Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital announced an offer to acquire 12.2% stake in GlobeImmune, Inc. for $7,000.	CI
2017	NantCell, Inc. Exercises Option for Licensing Agreement with GlobeImmune, Inc. for GI-6100	CI

GlobeImmune Weighing A Potential Sale

August 14, 2015 at 12:00 am EDT

GlobeImmune Inc. (NasdaqCM:GBIM) is exploring a potential sale. GlobeImmune officials said the company now has six full time employees down from 22 at the start of 2015 and is eyeing a sale of some or all of its assets.

Latest news about GlobeImmune, Inc.

Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital announced an offer to acquire 12.2% stake in GlobeImmune, Inc. for $7,000.	22-05-05	CI
NantCell, Inc. Exercises Option for Licensing Agreement with GlobeImmune, Inc. for GI-6100	17-08-30	CI
NantCell, Inc. Enters into Licensing Agreement with GlobeImmune, Inc. for GI-4000	17-08-30	CI
NantCell, Inc. Enters into Licensing Agreement with GlobeImmune, Inc. for GI-6207 and GI-6301	17-08-30	CI
GlobeImmune, Inc. announced a financing transaction	17-03-19	CI
Gilead Sciences, Inc. Terminates the Collaboration and License Agreement with GlobeImmune	16-11-17	CI
GlobeImmune Inc. Announces Management and Board Changes	16-11-17	CI
GlobeImmune Inc.(OTCPK:GBIM) dropped from S&P TMI Index	16-07-25	CI
GlobeImmune Inc.(OTCPK:GBIM) dropped from NASDAQ Composite Index	16-07-24	CI
Globeimmune, Inc Announces Financial Results for the First Quarter Ended March 31, 2016	16-05-12	CI
GlobeImmune Seeks Alternatives	16-05-12	CI
GlobeImmune Inc.(NasdaqCM:GBIM) dropped from CRSP US Total Market Index	16-03-21	CI
GlobeImmune Inc. Reports Earnings Results for the Year Ended December 31, 2015; Provides Update on Clinical Programs	16-03-16	CI
GlobeImmune Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	15-11-13	CI
GlobeImmune Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2015	15-08-14	CI
GlobeImmune Weighing A Potential Sale	15-08-14	CI
GlobeImmune Explores Strategic Alternatives	15-08-13	CI
Globeimmune, Inc. Enters into License Agreement with Celgene Corporation	15-08-04	CI
Kirk Christoffersen to Leave GlobeImmune Inc. as Vice President, Corporate Development, Effective Aug. 3, 2015	15-07-17	CI
GlobeImmune to Lay Off Majority of its Workforce	15-06-10	CI
GlobeImmune Explores Strategic Options	15-06-10	CI
GlobeImmune, Inc. Announces Line Results from GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients	15-05-27	CI
GlobeImmune Inc. Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute	15-04-22	CI
Globeimmune, Inc. Provides Update on Business and Clinical Programs; Reports Earnings Results for the Year Ended December 31, 2014	15-03-17	CI
3,628,245 Common Stock of GlobeImmune, Inc. are subject to a Lock-Up Agreement Ending on 27-DEC-2014.	14-12-26	CI

Chart GlobeImmune, Inc.

Duration

Period

More charts

Company Profile

GlobeImmune Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Companyâs Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. It has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Company's oncology product candidates include GI-6301, GI-6207 and GI-4000. The Company's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GLOBEIMMUNE, INC.	-.--%	5
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	115B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.31B
ARGENX SE	-3.99%	21.6B
BEIGENE, LTD.	-7.19%	18.23B
WUXI APPTEC CO., LTD.	-39.93%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.26B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.37B
LEGEND BIOTECH CORPORATION	-28.60%	8.28B

Bio Therapeutic Drugs